<DOC>
	<DOCNO>NCT00349284</DOCNO>
	<brief_summary>Type IIb dyslipidemia characterize elevate triglyceride ( TG ³ 150 mg/dL ) , elevate LDL-C level ( ³160 mg/dL ) . When addition , HDL-C low , presence lipid triad , elevate TG LDL-C low level HDL-C , seem confer additional CHD risk type patient , compare elevate LDL-C alone.Coadministration fenofibrate ezetimibe could provide complementary efficacy therapy improve atherogenic profile patient population .</brief_summary>
	<brief_title>A Controlled-Study Fenofibrate 145 mg Ezetimibe 10 mg Type IIb Dyslipidemic Patients With Features Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Type IIb dyslipidemia . Known hypersensitivity fibrates ezetimibe . Pregnant lactating woman . Contraindication fenofibrate ezetimibe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hyperlipidemia Combined feature metabolic syndrome , efficacy combination fenofibrate ezetimibe</keyword>
</DOC>